Evidence map›Paper›PMID 42549036›Full record

ArticleMolecular therapy. Oncology2026

Arming oncolytic Coxsackievirus B3 with Neoleukin-2/15 enhances growth inhibition of colorectal carcinomas and induces T cell activation.

Leslie Elsner, Maxim Girod, Ahmet Hazini, Anja Geisler, Lisanne Heimann, Babette Dieringer, Jackson Shipman-Mueller, Andreas Thiel, Robert Klopfleisch, Jens Kurreck and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Leslie ElsnerTechnische Universität Berlin, Department of Applied Biochemistry, Institute of Biotechnology, Berlin, Germany.
Maxim GirodTechnische Universität Berlin, Department of Applied Biochemistry, Institute of Biotechnology, Berlin, Germany.
Ahmet HaziniUniversity of Oxford, Department of Oncology, Old Road Campus Research Building (ORCRB), Roosevelt Drive, OX3 7DQ Oxford, UK.
Anja GeislerTechnische Universität Berlin, Department of Applied Biochemistry, Institute of Biotechnology, Berlin, Germany.
Lisanne HeimannTechnische Universität Berlin, Department of Applied Biochemistry, Institute of Biotechnology, Berlin, Germany.
Babette DieringerTechnische Universität Berlin, Department of Applied Biochemistry, Institute of Biotechnology, Berlin, Germany.
Jackson Shipman-MuellerBerlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany.
Andreas ThielSi-M "Der Simulierte Mensch", a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.
Robert KlopfleischFreie Universität Berlin, Department of Veterinary Medicine, Institute of Veterinary Pathology, Berlin, Germany.
Jens KurreckTechnische Universität Berlin, Department of Applied Biochemistry, Institute of Biotechnology, Berlin, Germany.
Sophie Van LinthoutBerlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany.
Henry FechnerTechnische Universität Berlin, Department of Applied Biochemistry, Institute of Biotechnology, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncolytic viruses (OVs) represent an emerging class of cancer immunotherapeutics. Arming OVs with immunomodulatory transgenes is a promising strategy to reshape the tumor microenvironment (TME) and enhance therapeutic efficacy. We developed the oncolytic Coxsackievirus B3 (CVB3) strain PD-H, which has previously shown antitumor activity in colorectal and pancreatic cancer models. Here, we evaluated the capacity of PD-H to express transgenes and investigated whether its antitumor efficacy in colorectal cancer can be enhanced by insertion of the interleukin-2 (IL-2) mimetic Neoleukin-2/15 (Neo-2/15). Transgene insertion was best tolerated at the VP1-2A junction of the PD-H polyprotein, with viral replication and cytotoxicity inversely correlating with insert size. Genetic stability depended on the host cell line, transgene sequence and transgene length, with inserts up to 350 bp remaining stable for at least 10 viral passages. PD-H-derived Neo-2/15 was biologically active and induced proliferation of human CD4

Indexed as

cancercolorectal carcinomaCoxsackievirus B3immunotherapyNeoleukin 2/15oncolytic virusPD-H

Identifiers

PMID42549036
PMCPMC13430168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.